Evidence map›Paper›PMID 28314188›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2017

Pharmaceutical analysis of a novel propargyl-linked antifolate antibiotic in the mouse.

John Hoody, Jeremy B Alverson, Santosh Keshipeddy, Patrick A Barney, Larissa Walker, Amy C Anderson, Dennis L Wright, Nigel D Priestley

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The Concept of Folic Acid in Health and Disease.Molecules (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

John HoodyDepartment of Chemistry and Biochemistry, The University of Montana, Missoula, MT 59812, United States.
Jeremy B AlversonDepartment of Chemistry and Biochemistry, The University of Montana, Missoula, MT 59812, United States.
Santosh KeshipeddyDepartment of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Road, Storrs, CT 06269, United States.
Patrick A BarneyDepartment of Chemistry and Biochemistry, The University of Montana, Missoula, MT 59812, United States.
Larissa WalkerDepartment of Chemistry and Biochemistry, The University of Montana, Missoula, MT 59812, United States.
Amy C AndersonDepartment of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Road, Storrs, CT 06269, United States.
Dennis L WrightDepartment of Pharmaceutical Sciences, University of Connecticut, 69 N. Eagleville Road, Storrs, CT 06269, United States.
Nigel D PriestleyDepartment of Chemistry and Biochemistry, The University of Montana, Missoula, MT 59812, United States. Electronic address: nigel.priestley@umontana.edu.
University of Montana · USUniversity of Connecticut · US

Funding

Propargyl-linked Antifolates Targeting Klebsiella pneumoniaeR01AI104841 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI WRIGHT, DENNIS L. · 2014 to 2018
$3.1M
Antimetabolites Effective against Resistant Gram-positive BacteriaR01AI111957 · NIAID · UNIVERSITY OF CONNECTICUT STORRS · PI WRIGHT, DENNIS L. · 2014 to 2017
$2.2M
Novel antibacterial agents derived from natural productsR41AI118104 · NIAID · PROMILIAD BIOPHARMA, INC. · PI PRIESTLEY, NIGEL D · 2016 to 2016
$296k
Development of stable isosteres of dihydrofolate reductase inhibitors as antibactR43AI106166 · NIAID · PROMILIAD BIOPHARMA, INC. · PI PRIESTLEY, NIGEL D · 2013 to 2013
$288k
NIAID NIH HHS R01 AI104841NIAID NIH HHS R01 AI111957NIAID NIH HHS R41 AI118104NIAID NIH HHS R43 AI106166
6 · The paper itself

Abstract

Antimicrobial resistance to current antibiotics is a significant public health problem and the need for new antibiotics is a compelling one. We have been developing a new series of antibiotics, propargyl-linked diaminopyrimidines, based on the structure of trimethoprim. To date we have discovered compounds that are effective inhibitors of dihydrofolate reductase (the target of trimethoprim), that are potent antibiotics in vitro against a range of Gram-positive pathogens including methicillin-resistant S. aureus, and that are non-toxic in mammalian cell culture. In this study we report the development of an LC-MS-based protocol for the quantification of our lead antibiotic 37D1-UCP1099 and the application of this assay to follow the concentration of the compound in mouse plasma after intraperitoneal administration. Extraction of 37D1-UCP1099 from mouse plasma was achieved through a liquid-liquid extraction with ethyl acetate. Separation was performed utilizing a reverse-phase C18 column with a ten minute isocratic elution using 47:53 (v/v) 10mM NH

Indexed as

AnimalsAnti-Bacterial AgentsChromatography, High Pressure LiquidFemaleFolic Acid AntagonistsInjections, IntraperitonealLimit of DetectionLiquid-Liquid ExtractionMiceSpectrometry, Mass, Electrospray IonizationAnti-Bacterial AgentsFolic Acid AntagonistsAntibioticFolateLC–MSMousePropargyl-linkedTrimethoprim

Identifiers

PMID28314188
PMCPMC5635995
OpenAlexW2593966954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.